Shanghai Junshi Biosciences Co (HKSE:01877) FCF Margin % : -154.64% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Shanghai Junshi Biosciences Co's Free Cash Flow for the three months ended in Mar. 2024 was HK$-639.7 Mil. Shanghai Junshi Biosciences Co's Revenue for the three months ended in Mar. 2024 was HK$413.7 Mil. Therefore, Shanghai Junshi Biosciences Co's FCF Margin % for the quarter that ended in Mar. 2024 was -154.64%.

As of today, Shanghai Junshi Biosciences Co's current FCF Yield % is -4.31%.

The historical rank and industry rank for Shanghai Junshi Biosciences Co's FCF Margin % or its related term are showing as below:

HKSE:01877' s FCF Margin % Range Over the Past 10 Years
Min: -114356.17 Med: -227.01 Max: -37.97
Current: -776.83

During the past 8 years, the highest FCF Margin % of Shanghai Junshi Biosciences Co was -37.97%. The lowest was -114356.17%. And the median was -227.01%.

HKSE:01877's FCF Margin % is ranked worse than
72.25% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs HKSE:01877: -776.83

Shanghai Junshi Biosciences Co FCF Margin % Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co FCF Margin % Chart

Shanghai Junshi Biosciences Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-264.51

-131.14

-37.97

-149.25

-189.51

Shanghai Junshi Biosciences Co Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial														-331.52	-18.28	60.21	-	-154.64

Competitive Comparison of Shanghai Junshi Biosciences Co's FCF Margin %

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Junshi Biosciences Co's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's FCF Margin % falls into.

Shanghai Junshi Biosciences Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Shanghai Junshi Biosciences Co's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-3114.578	/	1643.457
	=	-189.51 %

Shanghai Junshi Biosciences Co's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-639.689	/	413.668
	=	-154.64 %

Shanghai Junshi Biosciences Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

8SJ:Germany 688180:China

Address

Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines